J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says
Nov 15 (Reuters) - Johnson & Johnson JNJ.N could announce a deal as soon as Monday to buy Texas-based biotech Ollin Biosciences for up to $3.4 billion, the Financial Times said, citing people familiar with the matter.
Here are some details:
Under the terms being discussed, J&J could pay Ollin's backers $2.2 billion in cash upfront and a further $1.2 billion in potential milestone payments, the paper said
Ollin raised $330 million in June to advance late-stage studies of its experimental eye disease drug OLN324, to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD), two leading causes of vision loss
Reuters could not immediately verify the report. Neither Johnson & Johnson nor Ollin Biosciences immediately responded to Reuters' requests for comment outside business hours
J&J acquired biotech Firefly Bio for $1 billion in cash this year, as it looked to expand its cancer drug pipeline. The company also bought drugmaker Intra-Cellular Therapies for $14.6 billion in 2025 to boost its presence in the market for neurological disorder treatments